Varma Mutual Pension Insurance Co Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Varma Mutual Pension Insurance Co purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 18,488 shares of the biopharmaceutical company’s stock, valued at approximately $11,528,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $26,000. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $29,000. Finally, Trust Co. of Vermont acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $834.04 on Monday. The firm has a market capitalization of $85.87 billion, a PE ratio of 20.61, a P/E/G ratio of 1.42 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00. The firm’s 50-day simple moving average is $697.09 and its 200 day simple moving average is $716.46. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm posted $12.81 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Analyst Ratings Changes

A number of equities research analysts recently commented on REGN shares. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Canaccord Genuity Group cut their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Truist Financial raised their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $801.70.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at $482,400. This trade represents a 39.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock valued at $1,090,030 in the last ninety days. Corporate insiders own 6.97% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.